TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02240875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO Z at 5 x 10^10 vp
Description: High dose cAd3-EBO Z

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO Z at 5 x 10^10 vp
Description: High dose cAd3-EBO Z

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4.4x10^8 TCID50s MVA-BN® Filo
Description: High dose MVA-BN® Filo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4.4x10^8 TCID50s MVA-BN® Filo
Description: High dose MVA-BN® Filo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4.4x10^8 TCID50s MVA-BN® Filo
Description: High dose MVA-BN® Filo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.2x10^8 TCID50s MVA-BN® Filo
Description: Low dose MVA-BN® Filo
Study: NCT01472185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants are instructed to continue the exercise regimen prescribed by their physician.
Study: NCT02240875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.2x10^8 TCID50s MVA-BN® Filo
Description: Low dose MVA-BN® Filo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.2x10^8 TCID50s MVA-BN® Filo
Description: Low dose MVA-BN® Filo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.2x10^8 TCID50s MVA-BN® Filo
Description: Low dose MVA-BN® Filo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.2x10^8 TCID50s MVA-BN® Filo
Description: Low dose MVA-BN® Filo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4.4 x 10^7 TCID50s MVA-BN® Filo
Description: Very low dose MVA-BN® Filo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4.4 x 10^7 TCID50s MVA-BN® Filo
Description: Very low dose MVA-BN® Filo
Study: NCT02483299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage tablets and Victoza
Study: NCT00138632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787
Description: Visudyne® + PTK787, 500 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787
Description: Visudyne® + PTK787 1000 mg/day
Study: NCT00138177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study: NCT04095273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Study drugs will be administered as scheduled
Study: NCT02830841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning(RIPC)
Description: After anesthesia induction, donors or recipients will be treated with automated blood pressure cuffs on their upper arms to receive RIPC by cuff inflation (to 15mmHg above systolic pressure) for 5 minutes and left inflated for 5 minutes. The cuff will then be deflated to 0 mm Hg and left uninflated for 5 minutes. This cycle will be performed 3 times in total.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning(RIPC)
Description: After anesthesia induction, donors or recipients will be treated with automated blood pressure cuffs on their upper arms to receive RIPC by cuff inflation (to 15mmHg above systolic pressure) for 5 minutes and left inflated for 5 minutes. The cuff will then be deflated to 0 mm Hg and left uninflated for 5 minutes. This cycle will be performed 3 times in total.
Study: NCT04095273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda®)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda®)
Description: Study drugs will be administered as scheduled
Study: NCT00138632

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visudyne® + Placebo
Study: NCT02396940

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D HD laparoscopy
Description: Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 2D HD laparoscopy
Description: Placebo
Study: NCT02519556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiatop
Description: Dilute one sachet in 100ml of water and take it in every morning, once a day for 6 months.
Study: NCT04095273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda®)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda®)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda®)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda®)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda®)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda®)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda®)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda®)
Description: Study drugs will be administered as scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda®)
Description: Study drugs will be administered as scheduled
Study: NCT01933217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02291744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resection of primary lesion
Description: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle, and resection of primary lesion with metastatic colon cancer
Study: NCT03469609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mucous fistula refeeding
Description: Transfer of infants' own stool
Study: NCT02291744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle,
Study: NCT03981952

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Invasive Salmonella Disease Vaccine (6.25 µg)
Description: 6.25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Invasive Salmonella Disease Vaccine (12 µg)
Description: 12 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Invasive Salmonella Disease Vaccine (25 µg)
Description: 25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C)
Description: The highest, well-tolerated dose of the conjugate vaccine among Cohorts A-C is administered via one or two intramuscular injection(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL of buffer and preservative is administered via one or two intramuscular injections(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL of buffer and preservative is administered via one or two intramuscular injections(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL of buffer and preservative is administered via one or two intramuscular injections(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL of buffer and preservative is administered via one or two intramuscular injections(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
Study: NCT03647137

Intervention type: OTHER
Intervention: Detailed motor testing, including FoG, in PD subjects
Description: Subjects with PD with and without freezing of gait (FoG) will undergo a biomechanical assessment during a FoG provocation protocol in both the dopaminergic on and off state.

Intervention type: OTHER
Intervention: Detailed motor testing, including FoG, in PD subjects
Description: Subjects with PD with and without freezing of gait (FoG) will undergo a biomechanical assessment during a FoG provocation protocol in both the dopaminergic on and off state.
Study: NCT02297230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab. Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose. If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses. Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab. Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose. If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses. Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).
Study: NCT03757468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthodontic - maxillary expansion
Description: After appliance placement, the screw (hyrax or leaf type) will be activated until overcorrection. Expansion will be considered adequate when the occlusal surface of the first maxillary palatal cusp contact the occlusal surface of the mandibular first molar facial cusp. When will be achieved, the expander will stay in place for 10 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic - maxillary expansion
Description: After appliance placement, the screw (hyrax or leaf type) will be activated until overcorrection. Expansion will be considered adequate when the occlusal surface of the first maxillary palatal cusp contact the occlusal surface of the mandibular first molar facial cusp. When will be achieved, the expander will stay in place for 10 months.
Study: NCT03647137

Intervention type: OTHER
Intervention: Detailed motor testing, including FoG, in PD subjects
Description: Subjects with PD with and without freezing of gait (FoG) will undergo a biomechanical assessment during a FoG provocation protocol in both the dopaminergic on and off state.
Study: NCT04129944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UBX0101
Description: Investigational drug intra-articular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UBX0101
Description: Investigational drug intra-articular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UBX0101
Description: Investigational drug intra-articular injection
Study: NCT04129944

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intra-articular injection
Study: NCT00178724

Intervention type: OTHER
Intervention: No Treatment Given
Description: Intervention is not given.
Study: NCT02943460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablet(s) administered orally once daily with food
Study: NCT04043702

Intervention type: DRUG
Intervention: The intervention being studied
Description: Intervention Other Names have not been specified

Intervention type: DRUG
Intervention: The intervention being studied
Description: Intervention Other Names have not been specified

Intervention type: DRUG
Intervention: The intervention being studied
Description: Intervention Other Names have not been specified

Intervention type: DRUG
Intervention: The intervention being studied
Description: Intervention Other Names have not been specified
Study: NCT02645487

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Radiation, Stereotactic Radiosurgery Size \<= 1cm: 24 Gray (Gy); + 3 Gy incremental escalation up to 30 Gy \>1-2cm: 21 Gy; + 3 Gy incremental escalation up to 27 Gy \>2-3cm: 18 Gy; + 3 Gy incremental escalation up to 24 Gy
Study: NCT02105701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir + Elbasvir
Description: FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir + Elbasvir
Description: FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir + Elbasvir
Description: FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.
Study: NCT03514693

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI
Description: Ipsilateral circumferential PVI is the recommended PVI strategy. The success of PVI is defined as the achievement of the dissociation of PV potentials in all PVs. Disappearance of PV potentials is reconfirmed at the end of the procedure, a minimum of 20 minutes after the initial success of PVI.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PVI plus additional ablation
Description: In addition to PVI, CFAE ablation, linear ablation, or both; the choice of which is decided by the physician
Study: NCT00694590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Drug Course 1: plerixafor (20mg/mL). Dose escalation starting with 80 mcg/kg then 160, 240, 320, 420, and 540 mcg/kg, or to de-escalate to 40mcg/kg. Dosing 3 times/week for 3 weeks beginning at start of second week. Rituximab is also administered 3 times per week for 4 weeks using a fixed dose of 100 mg on Day 1 and a dose of 375 mg/m2 for all subsequent doses.~Drug Course 2: plerixafor (20 mg/m) same dose as course 1. Dosing 3 times/week for 4 weeks. Rituximab is also administered 3 times per week for 4 weeks using a dose of 375 mg/m2 for all doses.
Study: NCT01881932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture using Seirin® needles
Description: Participants will receive acupuncture weekly until the end of chemotherapy.~Subjects will receive acupuncture at documented acupoints. To improve blinding effect, the acupuncturist will also tap 2 guiding tubes at 2 sham points , and immediately affix a pair of needles to the surface of the same points with adhesive tape, without needle insertion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Acupuncture using Park Sham placebo acupuncture device
Description: Participants will receive sham acupuncture until the end of chemotherapy.~Acupuncturist will insert Park Sham Devices, non-penetrating sham acupuncture device consisting of a retractable needle and an adhesive tube into the sham points, and then immediately apply 2 pieces of adhesive tape next to the needles. In addition, she will tap a mock plastic needle guiding tube on the surface of each of the 8 true points in the arm and leg to produce some discernible sensation and then immediately apply a needle with a piece of adhesive tape to the dermal surface, without needle insertion.
Study: NCT01929603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling
Description: Blood sampling to measure olaparib, rifampicin and 4β-hydroxycholesterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin (CYP inducer) 600mg taken once daily from Day 5 to Day 14 (Part A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib tablet dosing
Description: Olaparib 300mg tablet taken on Days 1 and 14 (Part A). Part B dosing is 300mg olaparib bi-daily
Study: NCT02202577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine - Isopropyl alcohol
Description: Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine Scrub and Paint
Description: Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
Study: NCT02943460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match cilofexor
Description: Tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match cilofexor
Description: Tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match cilofexor
Description: Tablet(s) administered orally once daily with food
Study: NCT04537039

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Frailty screening for people over 65 living at home.
Description: The home care services will carry out the SEGA-A test.
Study: NCT04294667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZP
Description: Subjects will receive dapirolizumab pegol at prespecified time-points.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo at prespecified time-points.
Study: NCT00953381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg ilaprazole
Description: One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg ilaprazole
Description: Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg ilaprazole
Description: Four 5-mg ilaprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mg omeprazole
Description: One 20-mg omeprazole capsule (AstraZeneca, Losec) together with four placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
Study: NCT00661973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: inhaled budesonide (turbohaler) 400 micrograms twice a day for 4 weeks